Term
|
Definition
|
|
Term
|
Definition
| HIV+, acquired immune deficiency syndrome, immune system failing |
|
|
Term
|
Definition
| anti-retroviral therapy, drug combination |
|
|
Term
|
Definition
| refers to a drug or ART (not previously on drugs), *some patients might be infected by someone on stable medication |
|
|
Term
|
Definition
| previously on ART (specific class or any ART) |
|
|
Term
|
Definition
| brief elevation in viral load, transient, return to normal in most PTs, happens to 1/4pts on ART, *usually not highly elevated |
|
|
Term
|
Definition
| change in initial therapy due to medication intolerance, medication failure or virologic failure, change regimen (usually more complex) |
|
|
Term
|
Definition
| highly drug-experienced patient, running out of options, medication "recycling" |
|
|
Term
|
Definition
| most common in US, subtypes: B is most prevalent in US, more virulent, relatively easily transmitted |
|
|
Term
|
Definition
|
|
Term
|
Definition
| genotype-nucleoside mutation, phenotype-morphological change, tropism-change from environmental stimuli |
|
|
Term
|
Definition
| relationship of virus to CD4+ co-receptor |
|
|
Term
|
Definition
| HIV-1: chimpansee subspecies, west equatorial Africa |
|
|
Term
|
Definition
| sooty mangabeys, Guinea-Bissau (west Aftrica) |
|
|
Term
|
Definition
| orchestrate communication among other cell types of the immune system |
|
|
Term
| CD: “Clusters of Differentiation” |
|
Definition
| Cell-surface markers (proteins) that allow for categorization of T-cells (& other cell types) into specific lymphocyte subtypes, e.g., CD2+, CD3+, CD8+, etc. |
|
|
Term
|
Definition
| CD4 count < 200 or <14% total lymphocytes, infections (bacterial, fungal, protozoal, viral), malignancies (sarcoma, lymphoma) |
|
|
Term
|
Definition
| IV drugs, sex (unprotected), blood product transfusion, mother-to-baby, occupational exposure |
|
|
Term
|
Definition
| behavioral modification, safety devices, pre-exposure prophylaxis or PrEP, post-exposure prophylaxis |
|
|
